+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Eligard"

Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Thumbnail Image

Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • February 2025
  • 100 Pages
  • Global
From
Prostate Cancer Therapeutics Market - Product Thumbnail Image

Prostate Cancer Therapeutics Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Prostate Cancer in the United States: Understanding the Prostate Cancer Patient Experience - Product Thumbnail Image

Prostate Cancer in the United States: Understanding the Prostate Cancer Patient Experience

  • Report
  • January 2024
  • 129 Pages
  • United States
  • 3 Results (Page 1 of 1)
Loading Indicator

Eligard is a brand of luteinizing hormone-releasing hormone (LHRH) agonist, a type of drug used to treat breast cancer. It is used to reduce the amount of estrogen in the body, which can slow the growth of certain types of breast cancer. Eligard is administered as an injection, usually once a month, and is typically used in combination with other treatments such as chemotherapy and radiation. Eligard is one of several drugs used to treat breast cancer, and is part of a larger market of breast cancer drugs. This market includes other LHRH agonists, aromatase inhibitors, and targeted therapies. These drugs are used to treat different stages of breast cancer, from early-stage to advanced-stage. Companies in the Eligard market include Sanofi, Pfizer, AstraZeneca, Novartis, and Eli Lilly. Show Less Read more